| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJME058196 |
| P698 | PubMed publication ID | 16236745 |
| P2093 | author name string | Gabriel N Hortobagyi | |
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| trastuzumab | Q412616 | ||
| P304 | page(s) | 1734-1736 | |
| P577 | publication date | 2005-10-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Trastuzumab in the treatment of breast cancer | |
| P478 | volume | 353 |
| Q53243856 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. |
| Q55332855 | A Nomogram for Distinction and Potential Prediction of Liver Metastasis in Breast Cancer Patients. |
| Q37679799 | A comparative study on the physicochemical and biological stability of IgG1 and monoclonal antibodies during spray drying process |
| Q36085663 | A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients |
| Q93138559 | A new agent in the family of antibody-drug conjugates |
| Q35941981 | A terrible beauty: a physician's story of ovarian cancer. |
| Q36798432 | Adjuvant systemic therapy for operable breast cancer. |
| Q36680818 | Adjuvant therapy for patients who have node-positive breast cancer |
| Q55181611 | Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. |
| Q42671435 | Adjuvant trastuzumab for breast cancer |
| Q33957896 | Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. |
| Q34616517 | Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers |
| Q38613552 | Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes |
| Q36618624 | Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). |
| Q61899631 | Benefit of taxanes as adjuvant chemotherapy for early breast cancer |
| Q37947902 | Beyond trastuzumab: new treatment options for HER2-positive breast cancer |
| Q33446778 | Breast cancer (non-metastatic) |
| Q55176357 | Breast cancer (non-metastatic). |
| Q28068290 | Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management |
| Q34022038 | Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value |
| Q34475414 | Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. |
| Q28066285 | Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion |
| Q33731346 | Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort |
| Q33892746 | Construction and evaluation of a novel humanized HER2-specific chimeric receptor |
| Q39337108 | Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. |
| Q33533628 | Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer |
| Q54534471 | Dual silencing of epidermal growth factor and insulin-like growth factor 1 receptors significantly limits growth of nasopharyngeal carcinoma in nude mice. |
| Q37687387 | ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas |
| Q35028823 | Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts |
| Q41608794 | Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification |
| Q36546414 | First description of a sporadic breast cancer in a woman with BRCA1 germline mutation |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q48014457 | HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. |
| Q55439955 | HER2 status in breast cancer--an example of pharmacogenetic testing. |
| Q43230819 | Harmful impact of EU clinical trials directive |
| Q48034907 | Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer |
| Q36178400 | Immune microenvironment in tumor progression: characteristics and challenges for therapy |
| Q47587077 | Information overload in oncology practice and its potential negative impact on the delivery of optimal patient care |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q83915531 | Keynote comment: Cancer drug pricing in the USA |
| Q45241774 | Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer. |
| Q36917485 | Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. |
| Q80130796 | Linking oncogenic pathways with therapeutic opportunities |
| Q41547969 | Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. |
| Q39095238 | Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma |
| Q36410651 | Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer |
| Q28084024 | Mechanisms involved in breast cancer liver metastasis |
| Q37123317 | Media Hyping and the "Herceptin Access Story": An Analysis of Canadian and UK Newspaper Coverage |
| Q26798404 | Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy |
| Q21284509 | MicroRNAs in the DNA Damage/Repair Network and Cancer |
| Q30496357 | Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays |
| Q36955065 | Molecular targeted therapies for breast cancer treatment |
| Q57784935 | Monitoring Src status after dasatinib treatment in HER2+ breast cancer with Zr-trastuzumab PET imaging |
| Q43245419 | Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors |
| Q51780346 | Next-generation sequencing and epigenome technologies: potential medical applications |
| Q59543794 | Nutrition et prévention tertiaire des cancers. y a-t-il des recommandations ? |
| Q33284158 | Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. |
| Q88790399 | Past, present and future of gene expression-tailored therapy for lung cancer |
| Q37965048 | Personalized cancer medicine and the future of pathology. |
| Q33934494 | Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study |
| Q89604993 | Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion |
| Q24306910 | Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation |
| Q37544392 | Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells |
| Q55380623 | Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. |
| Q39657141 | Targeted microbeads for attraction and induction of specific innate immune response in the tumor microenvironment |
| Q34162501 | Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers |
| Q36114852 | Targeting HER2 Positive Breast Cancer with Chemopreventive Agents |
| Q38040407 | Targeting malignant mitochondria with therapeutic peptides. |
| Q91879447 | The Composite Planning Technique in Left Sided Breast Cancer Radiotherapy: A Dosimetric Study |
| Q54498075 | The ERBB network: at last, cancer therapy meets systems biology. |
| Q64917799 | The MAP3K7-mTOR Axis Promotes the Proliferation and Malignancy of Hepatocellular Carcinoma Cells. |
| Q93139736 | The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars |
| Q36681495 | The use of HER2 modulation in the adjuvant setting. |
| Q53761690 | Tissue Acquisition in Clinical Trials-Essential for Progress. |
| Q42868373 | Trastuzumab and congestive heart failure: what can we learn from use in the community? |
| Q37357924 | Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer |
| Q34564125 | Trastuzumab for early breast cancer: evolution or revolution? |
| Q36802271 | Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results |
| Q54979386 | Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. |
| Q36821168 | Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. |
| Q39163356 | Trastuzumab-associated cardiac events in the Persephone trial |
| Q36441450 | Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer |
| Q37085136 | Tumour immunity: effector response to tumour and role of the microenvironment |
| Q38702017 | Virus-based nanoparticles as platform technologies for modern vaccines |
| Q82921033 | [Non-metastatic breast cancer] |
Search more.